top of page

Investment Appraisal

Zeumed supports investors, boards, and senior decision-makers in assessing healthcare investments where value depends on how health systems, payers, and economies respond over time — rather than on stand-alone financial projections.

This work is rooted in health economics and policy analysis — adding to standard commercial and financial due diligence an understanding of how health systems and payers assess value, where reimbursement and payment models are heading, and how policy change affects long-term investment performance.

WHAT WE DO

Investment Appraisal Services

System-level assessment of healthcare investments

Evaluating proposed investments by analysing how they interact with healthcare systems and the wider economy — including effects on utilisation, capacity, public and private payers, and spillover effects beyond the immediate service or asset.

Impact of payment & reimbursement reform on investment value

Assessing how current and anticipated changes in payment models, reimbursement rules, and funding arrangements affect the viability and risk profile of healthcare investments over time — particularly where reforms alter incentives, volumes, or revenue predictability.

Regional market assessment & cross-market comparability

Providing investor-facing insight into how healthcare investments perform differently across regions — drawing on direct experience in Europe and the Gulf, where reimbursement structures, payer behaviour, and system architecture vary materially.

Translation of health system insight for investment decisions

Producing clear, decision-relevant analysis that allows investors and boards to understand how health system dynamics, payer behaviour, and policy choices shape investment outcomes — including downside risk and longer-term sustainability.

CASE STUDY

Health economics and system analysis for a major biotech investment

Zeumed provided health economics and system-level analysis that informed the investment assessment for a Gulf sovereign wealth fund considering a major biotech investment. The work examined how the investment would interact with regional health system dynamics, reimbursement structures, and long-term market conditions. Zeumed's analysis contributed to the assessment of an investment exceeding $200m.

Client type: Gulf sovereign wealth fund

Investment scale: $200m+

Sector: Biotech

Get in Touch

We welcome enquiries from investors, sovereign funds, and boards working on healthcare and life science investment decisions.

bottom of page